Clientron Exhibiting at EuroCIS and Embedded World 2016
Clientron Corp., a global leading provider of thin client, POS and embedded systems, announced it will be showcasing the latest advances in its product portfolios for POS terminals at EuroCIS February 23-25, 2016 in Dusseldorf, Germany. Meanwhile, Clientron is going to exhibit thin clients for virtual desktop solutions and IoT edge computers for sensors management at Embedded World February 23-25, 2016 in Nuremberg, Germany.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160216005005/en/
At EuroCIS 2016, Clientron will show its commitment to fulfill demands of smart retail and hospitality industry with innovative products, including brand new all-in-one POS terminals and various POS peripherals with the green benefit, reliability, efficiency. Aimed at the new frontier of POS market segment, Clientron provides the all new POS terminal Bello 650/650w with 15” / 15.6” widescreen and power efficient Intel Bay Trail quad-core processor. Clientron will also introduce the butterfly light-weight all-in-one POS terminal Wing series with new flexible dual-hinge stand design; the mainstream Ares650 series with updated ultra-slim system enclosure; Both the Wing350w and Ares650 win the “Taiwan Excellence Award 2016” with innovation and the best quality design. In addition, Clientron offers the most powerful POS terminal Evo770, equipped with Intel Core-i processor and a big crystal-clear 17” touch display, targets at the niche market segment. Moreover, many extended portfolios of integrated POS peripherals will also be shown in this event.
Meantime, at Embedded World 2016, Clientron will provide the full range of thin clients and virtual desktop solutions from cost effective ARM-based platform to high performance x86 quad-core platform. In addition, Clientron is going to display the smart IoT(Internet of Things) concept by demonstrating its brand new IoT edge computer with analytics capabilities for smart sensors management and actuators control.
“With many years of industry design experience, Clientron works deeply with partners and developers to implement and utilize thin clients, POS and embedded systems for the variety demands from vertical markets,” said Kelly Wu, President & CEO of Clientron Corp. To know more about Clientron’s custom design, manufacturing capabilities and services, please visit Clientron at booth No. 2-551, Hall 2, Exhibition Centre Nuremberg, Embedded World 2016 and booth No.10D35, Hall 10, Messe Dusseldorf, EuroCIS 2016. Clientron website: www.clientron.com
Clientron was founded in 1983. The company is dedicated to providing global intelligent solutions to our Clients. With design, manufacturing and service abilities, Clientron offers high-quality and high-performance computing platforms including Thin Client, POS and Intelligent Systems. Our vision and commitments at Clientron are to continuously provide better IoT client solutions and services for our partners and customers to build an intelligent e-World. Visit us at www.clientron.com .
Joan Chuang, 886-2-26987068
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom